Executive and expert insights

War stories, unique CEO insight and bold new ideas

EXECUTIVE AND EXPERT INSIGHTS

Carmell Therapeutics advances plasma-based products with $4m Series B support

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Investor perspective: Sander Slootweg

Looking back at the past year, 2017 has proven to be a pretty successful ye...

Read More

Life sciences IPOs: Five things to consider

After spending all day on Wednesday 7 February at Biotech & Money’s IPO wor...

Read More

Desperately seeking alpha: the quest for value

"VC investor seeking long-term relationship. WLTM small cap, early-stage, o...

Read More

Leveraging larger capital pools in Europe

On 5 February 2018, the 4th annual Biotech and Money/Medtech and Money Worl...

Read More

The growth finance landscape in biotech 

The state of the market While the European venture capital market has faced...

Read More

INFOGRAPHIC: 2018 INVESTOR PERCEPTION SURVEY HIGHLIGHTS

This infographic presents key findings from the 2nd Biotech and Money Inves...

Read More

CRISPR in Europe: patent protection and the importance of robust priority claims 

CRISPR, the revolutionary gene-editing technology, presents huge opportunit...

Read More

STORM Therapeutics leads the way in RNA epigenetics

Key learnings: STORM Therapeutics is developing small molecule inhibitors o...

Read More

Biotech vs medtech: divergence in intellectual property strategy

The landscape of innovation and investment in the healthcare sector has cha...

Read More

Biotech vs medtech: differences in mapping an IP portfolio

IP portfolio management is often overlooked, but is extremely important if ...

Read More

The New Cambrian Era for Biotech Start-ups

Healthcare is the hottest new sector for start-ups when it comes to new tec...

Read More

Anatomy of a…biotech IPO: Q&A with Neil Clark

On Tuesday 6 February 2018, leading life sciences companies will share thei...

Read More

Anatomy of a…private finance raise: Q&A with Martin Frost

On Tuesday 6 February 2018, leading life sciences companies will share thei...

Read More

Anatomy of a…medtech IPO: Q&A with Richard Davies

On Tuesday 6 February 2018, leading life sciences companies will share thei...

Read More

Case update: Loss of priority leads to revocation of key CRISPR patent

In February 2017, Gill Jennings & Every reported on the preliminary opinion...

Read More

Anatomy of a…hybrid business model: Q&A with Darrin Disley

On Tuesday 6 February 2018, leading life sciences companies will share thei...

Read More

Can I patent my biotechnological invention in Europe? 

Significant discoveries and developments in biotechnological research in re...

Read More

Learn how to protect and manage your intellectual property

A strong intellectual property (IP) position can be the deciding factor in ...

Read More

Biotech and medtech seed funding: what lies ahead?

The 4th annual Biotech and Money/Medtech and Money World Congress will offe...

Read More

Stent Tek sees development ramp up following Series A investment

Key learnings: Medical device company Stent Tek successfully closed its Ser...

Read More

Winner’s spotlight: Verona Pharma

Key learnings: Verona Pharma won the Life Science IPO of the Year Award at ...

Read More

Transatlantic investment: barriers and benefits for life sciences

On Monday 5 February 2018, leading investors will come together in London t...

Read More

Investorview: Proactively Bridging The Early Stage Funding Gap

Sinclair Dunlop, Managing Partner at Epidarex Capital Venture capital firm ...

Read More

Boult Wade Tennant: Aligning patent strategy and commercial aims in life sciences

Key learnings: Boult Wade Tennant provides international patent and trade m...

Read More

Investorview: Dr Z Haroon on Julz Co’s recent investments

Julz Co focuses on healthcare investments across the US, Europe, and Asia-P...

Read More

How Newcastle Science Central is helping to alleviate the UK’s skill shortage in big data

Q&A with Professor Paul Watson, Director of the Digital Institute and Profe...

Read More

How IP can support investment and funding in biotech innovations

Isobel Finnie, Partner and UK and European patent attorney within the Chemi...

Read More

Garry Kasparov: Reframing the conversation on AI and big data

Key learnings: On 14 November, former world chess champion, business speake...

Read More

Ali Mortazavi: On genomic data and pivotal moments for RNAi

On 14 November, RNA therapeutics company Silence Therapeutics hosted a pane...

Read More

Dr Annalisa Jenkins: On RNAi, her new chairmanship, and the importance of female role models

In October 2017, RNA therapeutics company Silence Therapeutics appointed Dr...

Read More

Winner’s spotlight: Oxford BioMedica

Key learnings: Oxford BioMedica was named winner in the UK Public Finance R...

Read More

How is investment in life sciences changing?

Where do you see the most opportunity in life sciences? What are your expec...

Read More

An investor’s outlook on the advanced therapies industry

Investment and funding sources are always at the heart of conversations aro...

Read More

Winner’s spotlight: Artios Pharma

Key learnings: Artios Pharma scooped two awards at the Biotech and Money Aw...

Read More

WideCells sets course for synergistic growth

Key learnings: WideCells Group has achieved some significant milestones thi...

Read More

Winner’s spotlight: Carrick Therapeutics

Key learnings: At this year’s Biotech and Money Awards, Carrick Therapeutic...

Read More

Top five biotech developments in the last 10 years and their importance

Biotech is one of the fastest growing industry sectors and, with the pace o...

Read More

Winner’s spotlight: Horizon Discovery's Darrin Disley

Key learnings: Horizon Discovery’s Dr Darrin Disley was voted UK Public Lif...

Read More

Winner’s spotlight: Horizon Discovery

Key learnings: Horizon Discovery was named winner in the Public Life Scienc...

Read More

Jane Griffiths: Pharma's role in the evolving healthcare landscape

Key learnings:  On 13 November 2017, Jane Griffiths, Global Head at Actelio...

Read More

Crowdfunding highlight: combating antimicrobial resistance

Antibiotics have been the miracle treatment for bacterial infections ever s...

Read More

Winner’s spotlight: F-star

Key learnings: F-star won the UK Life Science Deal of the Year Award at the...

Read More

Winner’s spotlight: F-star's John Haurum 

Key learnings: F-star’s John Haurum was named UK Private Life Science CEO o...

Read More

The 4th annual Biotech and Money / Medtech and Money World Congress 2018

The 4th annual Biotech and Money / Medtech and Money World Congress is a hi...

Read More

Winner’s spotlight: Microbiotica

Key learnings: Microbiotica was named winner in the Life Science Spin-Out o...

Read More

GDPR: Practical tips for the life sciences sector

Key learnings: The General Data Protection Regulation (GDPR) will bring abo...

Read More

GDPR: Key changes for life sciences organisations

Key learnings: The General Data Protection Regulation (GDPR) will come into...

Read More

What are the challenges and opportunities facing the healthcare sector?

Key learnings: On 13 November 2017, the life science and investment communi...

Read More

SkinBioTherapeutics on track with post-IPO milestones

Key learnings: SkinBioTherapeutics’ SkinBiotix® technology has passed third...

Read More

Winner’s spotlight: Bicycle Therapeutics

Key learnings: Bicycle Therapeutics was named Life Science Growth Company o...

Read More

What does the future hold for digital health investment?

Key learnings: The Biotech and Money community gathered for Biotechs and th...

Read More

Investor insights: The path to career success in life sciences

Key learnings: VC investors gathered at the Future Investor Forum 2017 to d...

Read More

2017 Biotech and Money Assembly and Awards Gala Dinner

A record number turned out for the annual Biotech and Money Assembly and Aw...

Read More

From Strength to Strength: Unpacking Clinigen's Route to Success

Putting patient care at the heart of its mission, Clinigen’s unique approac...

Read More

[Webinar Recording] The Current State of the M&A Landscape

Are you considering M&A transactions as a potential exit strategy, step to ...

Read More

[Webinar Recording] The Anatomy of a successful IPO

On the 27th June, we spoke to an expert panel to discuss the how, when, wha...

Read More

Will Horizon successfully navigate the path to profit?

Currently one of the most successful life science companies in the country,...

Read More

Management to investors: the communicative conundrum

We have published our annual investor perception survey, confirming or disp...

Read More

All in the Delivery - Interview with Simon Newman, CSO, Ryboquin

Biotech and Money recently talked to Simon Newman, CSO of Ryboquin, about t...

Read More

Interview with Daniel Oliver, CEO of Capital Cell

Daniel Oliver, CEO of Capital Cell, recently took the time to grant us an i...

Read More

Patenting problems specific to the biotech and healthcare sector

This is the fourth and final article in our series that aims to provide tip...

Read More

Nine things we learned from Centauri CEO Mike Westby

Biotech and Money recently talked to Mike Westby, CEO of Centauri, about th...

Read More

Interview with Dr Sara Nunez-Garcia, Principal, Sofinnova Partners

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

Read More

What are the most important lessons to be learnt from the European immunotherapy and cell & gene therapy industries?

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

Read More

Bionure breaks the records raising more than 1M€

Highlights Capital Cell’s crowdfunding campaign - Bionure - overfunds with ...

Read More

United Data in the United Kingdom: Congenica Diagnoses a Bright Future for UK Life Science Technologies

Tom Weaver CEO Congenica Using data analytics and applying their software t...

Read More

Open Window in the West? Deciding whether to pursue a US IPO

By Kristian Wiggert Partner Covington & Burling LLP, London The recent stro...

Read More

The impact of other people’s IP on you

This is the third in a series of four articles which aim to provide tips fo...

Read More

Eyeing up the global aesthetics market

Here are some lessons we learned during a recent interview with CFO Alan Ol...

Read More

10 things we learned from Medicines Discovery Catapult CEO Chris Molloy

With a strong focus on the collaboration needed to solve problems common to...

Read More

How to make your IP investable

This is the second in a series of four articles which aim to provide tips f...

Read More

Of Mice and Men: Kymab scurries up the biologics ladder

Using the pioneering Kymouse human antibody expression platform, Kymab are ...

Read More

What is Medtech?

Medtech is a very broad sector – it covers any technology that can be used ...

Read More

How to make your IP investable

At the core of any biotech company is an innovative piece of science which ...

Read More

7 questions with Isobel Finnie, Europe and UK patent attorney, Haseltine Lake

Biotech and Money recently caught up with Europe and UK patent attorney Iso...

Read More

Cancer’s Achilles heel has been found

In March of this year, an article published in Science made waves throughou...

Read More

Advice for Startups

Do your homework! Startups need to ‘do their homework’ when selecting a cro...

Read More

Equity Crowdfunding and life sciences

Equity crowdfunding is particulary suited to life sciences

Read More

How does equity investment work?

What is equity crowdfunding? To any average member of Joe public, the word ...

Read More

Maxcyte: Aiming to be the very best in cell therapy

Having recently listed on the London Stock Exchange, CEO Doug Doerfler tell...

Read More

8 Things we learned from Orphan Drugs Industry Advisory and Intelligence founder Christian Girard

Christian Girard, expert in orphan drugs, competitive intelligence, in/out ...

Read More

Collaborations in novel, highly potent drug classes

Biotech and Money had the opportunity to speak with Alastair Smith, the CEO...

Read More

Top 4 Tips you need to prepare for Biotech IPO

Biotech companies have fared well recently in the IPO market in both the US...

Read More

Some highlights from Biotech and Money's recent MedTech Webinar

On September 15th we spoke exclusively to a panel of MedTech CEOs and inves...

Read More

9 things we learned from F2G CEO Ian Nicholson

Ian has over 25 years of international experience in management and transac...

Read More

Mironid: Giving off all the right signals

Comprising a team with expertise in both development and commercialisation,...

Read More

Biotech and Money Assembly and Awards Gala Dinner

On the evening of the 6th September, we welcomed over 220 of the UK’s most ...

Read More

Transforming the lives of airways disease patients

Vectura, fresh from its recent acquisition of SkyePharma, holds a unique, b...

Read More

Equity Crowdfunding: the new Venture Capital?

SyndicateRoom – formed in 2013 by Gonçalo de Vasconcelos (CEO) and Tom Brit...

Read More

Innovative Cancer Detection and the £11M IPO

 Oncimmume, a leading UK early cancer detection company recently secured AI...

Read More

The Brexit Referendum Result

John Rountree, Managing Partner of Novasecta, a specialist pharmaceutical m...

Read More

9 Things we learned from Silence Therapeutics CEO Ali Mortazavi

Silence Therapeutics, formed in 1994 and with offices in London and Berlin,...

Read More

Syndicating for a £19M Series A financing

We find time with Paolo Paoletti, CEO of Kesios Therapeutics, a company wit...

Read More

Why Silence Therapeutics has the Midas touch

With interest in precision medicine growing, Silence’s ability to design, p...

Read More

Placements, Clinical Studies and the Utility of Parsortix

In this interview, we speak to Andrew Newland, the CEO of ANGLE plc, a comm...

Read More

Acquiring companies with realisable commercial tech

New acquisition vehicle Levrett comes online and immediately targets promis...

Read More

Enlarged Amryt Pharma joins AIM after reverse takeover

Joe Wiley, the CEO of Amryt Pharma, a speciality pharma company focused on ...

Read More

Securing follow-up funding investment

DefiniGEN CEO Marcus Yeo talks to Biotech and Money about his approach to s...

Read More

The role of the family office in life science investment

We have been sensing a growing trend of family office interest for getting ...

Read More
View More

Premium Members